Convalescent Plasma News and Research

RSS
Adapting biological research and development to COVID-19

Adapting biological research and development to COVID-19

SARS-CoV-2 evolution promoted by long-term infection in patient with B cell depletion

SARS-CoV-2 evolution promoted by long-term infection in patient with B cell depletion

Enisamium shows potential as antiviral therapy for COVID-19

Enisamium shows potential as antiviral therapy for COVID-19

Convalescent plasma is "futile" as COVID-19 treatment for critically ill patients, trial shows

Convalescent plasma is "futile" as COVID-19 treatment for critically ill patients, trial shows

Prevalence of adaptive and prolonged infections’ mutations in receptor-binding domain of SARS-CoV-2 spike protein

Prevalence of adaptive and prolonged infections’ mutations in receptor-binding domain of SARS-CoV-2 spike protein

Enveloped virus-like particle based vaccines potentially broaden immunity against SARS-CoV-2 variants

Enveloped virus-like particle based vaccines potentially broaden immunity against SARS-CoV-2 variants

Comparison of Pfizer, Moderna, J&J, AZ vaccines for neutralization titer, against Delta and other variants

Comparison of Pfizer, Moderna, J&J, AZ vaccines for neutralization titer, against Delta and other variants

Chronic COVID-19 and divergent variants of SARS-CoV-2

Chronic COVID-19 and divergent variants of SARS-CoV-2

A new SARS-CoV-2 variant (B.1.1.523) capable of escaping immune protections

A new SARS-CoV-2 variant (B.1.1.523) capable of escaping immune protections

People with natural immunity and subsequent mRNA vaccination can neutralize viral particles capable of resisting vaccine-induced antibodies

People with natural immunity and subsequent mRNA vaccination can neutralize viral particles capable of resisting vaccine-induced antibodies

Decline in SARS-CoV-2 neutralizing antibodies and unique cytokine profile in severe COVID-19 patients

Decline in SARS-CoV-2 neutralizing antibodies and unique cytokine profile in severe COVID-19 patients

Failures and findings from randomized clinical trials in COVID-19 convalescent plasma

Failures and findings from randomized clinical trials in COVID-19 convalescent plasma

Characterizing the flexibility of SARS-CoV-2 variant of concern spike proteins

Characterizing the flexibility of SARS-CoV-2 variant of concern spike proteins

Convalescent plasma shows no benefit in hospitalized COVID-19 patients

Convalescent plasma shows no benefit in hospitalized COVID-19 patients

Study identifies broadly neutralizing antibody panel against SARS-like viruses

Study identifies broadly neutralizing antibody panel against SARS-like viruses

Convalescent plasma does not reduce risk of intubation or death for COVID-19 hospitalized patients

Convalescent plasma does not reduce risk of intubation or death for COVID-19 hospitalized patients

Highly neutralizing human convalescent plasma reduces lung inflammation in SARS-CoV-2-infected macaques

Highly neutralizing human convalescent plasma reduces lung inflammation in SARS-CoV-2-infected macaques

Implications of persistent SARS-CoV-2 infection in patients with lymphoid malignancies

Implications of persistent SARS-CoV-2 infection in patients with lymphoid malignancies

Characterization of SARS-CoV-2 viral trajectory

Characterization of SARS-CoV-2 viral trajectory

Antibody cocktail neutralizes SARS-CoV-2 and has projected protection up to 12 months

Antibody cocktail neutralizes SARS-CoV-2 and has projected protection up to 12 months

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.